Coversyl Plus - Perindopril/Coversyl Plus is a combination therapy for the treatment of Essential hypertension.
Essential hypertension in subjects whose hypertension is not controlled by perindopril alone.
Treatment of essential hypertension. Coversyl Plus 5 mg/1.25 mg: Subjects whose blood pressure is not adequately controlled by perindopril alone. Coversyl Plus 10 mg/2.5 mg: Substitution therapy in patients already controlled with perindopril and Coversyl Plus given concurrently at the same dose level.
Treatment of essential hypertension. For patients whose blood pressure is insufficiently controlled by perindopril alone.
Treatment of essential hypertension. 5 mg/1.25 mg: Patients whose blood pressure is not adequately controlled on perindopril alone. 10 mg/2.5 mg: Substitution therapy for treatment of essential hypertension, in patients already controlled with perindopril and Coversyl Plus given concurrently at the same dose level.
It is used to treat adults with mild to moderate high blood pressure.
Coversyl Plus is a non-thiazide sulphonamide diuretic drug marketed by Servier, generally used in the treatment of hypertension, as well as decompensated cardiac failure. The US trade name for Coversyl Plus is Lozol. Coversyl Plus is marketed as Natrilix outside of the US. Combination preparations with perindopril (an ACE inhibitor antihypertensive) are also available.
It is described as a thiazide-like diuretic.
Stable coronary artery disease.
Perindopril (trade names Coversyl, Aceon) is a long-acting ACE inhibitor. It is used for patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction.